Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

HQY vs VEEV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VEEV Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 8–2 Matrix Metrics)

VEEV Overall Winner 6-Pillar Tally: HQY 1 – 4 VEEV (1 Tie) Matrix Metrics: HQY 2 – 8 VEEV

As of Nov 17, 2026, Veeva Systems Inc. (VEEV) is the stronger overall head-to-head candidate over HealthEquity, Inc (HQY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HQY carries a Unified Composite Score of 41.2/100 (SELL) at $101.86 (23.0x Forward P/E, 26.1% operating margin), whereas VEEV carries 48.5/100 (HOLD) at $290.25 (34.8x Forward P/E, 29.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HQY vs VEEV
HQY NASDAQ
HealthEquity, Inc
Services-Business Services, Nec
$101.86
-2.6% 1D
Market Cap $8.6B
TTM Revenue $1.36B
Forward P/E 23.0x
Beta / 30D Vol 0.28β · 38% Vol
Unified Composite Score
41.2 / 100 SELL
Tech 39.0 Fund 45.0 Flow 65.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.6% over 20 days), RSI 54
RSI-14: 53.7 · SMA20: $102.82 · SMA50: $96.43
VEEV NYSE Head-to-Head Winner
Veeva Systems Inc.
Services-Prepackaged Software
$290.25
-3.02% 1D
Market Cap $48.8B
TTM Revenue $3.46B
Forward P/E 34.8x
Beta / 30D Vol 0.39β · 20% Vol
Unified Composite Score
48.5 / 100 HOLD
Tech 45.0 Fund 53.0 Flow 68.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 40.9 · SMA20: $309.35 · SMA50: $292.48

6-Pillar Scorecard Institutional Category Breakdown (HQY 1 – 4 VEEV)

Columns: Metric · HQY · VEEV
1. Valuation Multiples HQY
Forward P/E 23.0x 34.8x
Trailing P/E 37.4x 49.4x
PEG Ratio 1.27x 1.16x
EV / Revenue 6.8x 13.6x
2. Growth & Scale VEEV
Revenue Growth (YoY) +7.6% +17.6%
Earnings Growth (YoY) +14.7% +39.5%
TTM Revenue (USD) $1.36B $3.46B
Market Cap $8.6B $48.8B
3. Profitability & Quality VEEV
Gross Margin 71.2% 75.0%
Operating Margin 26.1% 29.9%
Net Profit Margin 17.4% 29.3%
Return on Equity (ROE) 11.4% 14.4%
4. Balance Sheet & Cash Flow VEEV
Cash Generation (TTM) $437M $1.67B
Cash Flow Margin 32.1% 48.2%
Net Cash / Leverage $715M Net Debt (0.49x D/E) $1.66B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VEEV
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 35.8% (12th %ile) 45.0% (55th %ile)
Put/Call OI Skew N/A 0.71x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity 45.1% of Rev ($614M) 45.1% of Rev ($1.56B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Health Information Services Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HQY (2) vs VEEV (8)
Institutional Metric HQY VEEV Criterion Row Edge
Market Capitalization
Scale
$8.6B $48.8B Larger Scale VEEV
Trailing P/E Ratio
Valuation
37.4x 49.4x Lower Multiple HQY
Forward P/E Ratio
Valuation
23.0x 34.8x Lower Multiple HQY
Revenue Growth (YoY)
Growth
+7.6% +17.6% Higher Growth VEEV
Operating Margin (TTM)
Profitability
26.1% 29.9% Higher Margin VEEV
Net Profit Margin
Profitability
17.4% 29.3% Higher Margin VEEV
Return on Equity (ROE)
Capital Efficiency
11.4% 14.4% Higher ROE VEEV
52-Week Range Position
Momentum
78% ($73–$110) 80% ($148–$326) Stronger Trend VEEV
Beta / 30D Volatility
Risk Regime
0.28β · 38% Vol 0.39β · 20% Vol Lower Realized Risk VEEV
Unified Institutional Score
Composite Signal
41.2 / 100 (SELL) 48.5 / 100 (HOLD) Higher Composite VEEV
Trailing 12M Revenue (USD)
Operating Scale
$1.36B $3.46B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
71.2% 75.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.27x PEG · 6.8x EV/Rev 1.16x PEG · 13.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$437M ($715M Net Debt (0.49x D/E)) $1.67B ($1.66B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HQY +17.83 pp
HQY: +9.45% · VEEV: -8.38%
3M Horizon VEEV +17.65 pp
HQY: -2.01% · VEEV: +15.64%
6M Horizon VEEV +57.39 pp
HQY: +20.34% · VEEV: +77.73%
1Y Horizon HQY +1.15 pp
HQY: +0.09% · VEEV: -1.06%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period HQY Revenue VEEV Revenue HQY Op. Margin VEEV Op. Margin Margin Leader
FY2019 $290M $860M 27.0% 25.8% HQY
FY2020 $530M $1.10B 14.5% 25.9% VEEV
FY2021 $730M $1.47B 4.6% 25.8% VEEV
FY2022 $760M $1.85B -3.2% 27.3% VEEV
FY2023 $860M $2.16B 1.1% 21.3% VEEV
FY2024 $1.00B $2.36B 11.8% 18.2% VEEV
FY2025 $1.20B $2.75B 13.5% 25.2% VEEV
FY2026 $1.31B $3.20B 24.6% 28.7% VEEV

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HQY CONSOLIDATION
74d in phase · OBV NEUTRAL
Current IV 35.8%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact HQY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VEEV CONSOLIDATION
55d in phase · OBV DISTRIBUTION
Current IV 45.0%
IV Percentile 55th %ile
Put/Call OI Skew 0.71x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact VEEV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $299.28 · IV 50.8%

VEEV Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($29,928)

Compare $29,928 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 50.8% ATM IV.

5-DAY BULLISH SWING Liq B

Dec 18 $300 / $330 Bull Call Spread

Buy 1x $300C · Sell 1x $330C · 32d

Net Entry $1,140 Debit
T+5d @ +5% Move +$352 (+31%)
Max Risk / Buffer $1,140 Capped
5d Edge & Liquidity 0.8x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $280 / $260 Bull Put Spread

Sell 1x $280P · Buy 1x $260P · 32d

Net Entry $478 Credit
Max Credit / Yield +$478 (+31.4% RoM)
Max Risk / Buffer -8.0% Cushion ($1,522 Mgn)
5d Edge & Liquidity 71% PoP · Liq B
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 18 $270P / $300-$340C Seagull

Sell 1x $270P · Buy 1x $300/$340C · 32d

Net Entry $750 Debit
T+5d @ +5% Move +$805 (+18.3% RoM)
Max Risk / Buffer -9.8% Put Cushion ($4,408 Mgn)
5d Edge & Liquidity 0.8x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HQY Moat Profile Scale & Operating Efficiency Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $8.6B market capitalization and 26.1% operating margin.
OpEx & R&D Reinvestment 45.1% of Rev ($614M)
90D Engineering Disclosures 0 Published
VEEV Moat Profile Scale & Operating Efficiency Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $48.8B market capitalization and 29.9% operating margin.
OpEx & R&D Reinvestment 45.1% of Rev ($1.56B)
90D Engineering Disclosures 0 Published

Investor FAQ HQY vs VEEV Key Questions & Quantitative Answers

As of Nov 17, 2026, Veeva Systems Inc. (VEEV) is the stronger overall head-to-head candidate over HealthEquity, Inc (HQY) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). HQY carries a Unified Composite Score of 41.2/100 (SELL) at $101.86 (23.0x Forward P/E, 26.1% operating margin), whereas VEEV carries 48.5/100 (HOLD) at $290.25 (34.8x Forward P/E, 29.9% operating margin). Technically, HQY sits in a Markup phase (RSI 53.7, CONSOLIDATION options structure) and VEEV sits in a Neutral phase (RSI 40.9, CONSOLIDATION options structure).

VEEV leads the Growth & Scale pillar: HQY posts +7.6% YoY revenue growth and +14.7% YoY earnings growth on $1.36B TTM revenue (71.2% gross margin, 26.1% operating margin), compared with VEEV at +17.6% YoY revenue growth and +39.5% YoY earnings growth on $3.46B TTM revenue (75.0% gross margin, 29.9% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), HQY cumulative revenue shifted +351.7% while VEEV shifted +272.1%. In operating R&D and SG&A reinvestment, HQY deploys 45.1% of Rev ($614M) (0 90-day corporate R&D disclosures) versus 45.1% of Rev ($1.56B) (0 disclosures) for VEEV.

HQY screens cheaper on headline valuation multiples. HQY trades at 23.0x Forward P/E, 37.4x Trailing P/E, 1.27x PEG, and 6.8x EV/Revenue (32.1% FCF margin), whereas VEEV trades at 34.8x Forward P/E, 49.4x Trailing P/E, 1.16x PEG, and 13.6x EV/Revenue (48.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HQY (11.4% ROE) versus VEEV (14.4% ROE) capital efficiency.

In options market volatility and institutional positioning, HQY carries 35.8% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.28β · 38% Vol realized risk). By comparison, VEEV carries 45.0% implied volatility (55th %ile, Balanced (25th–60th %ile)), a 0.71x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.39β · 20% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.